Literature DB >> 599084

Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin.

R N Jones, C Thornsberry, A L Barry, P C Fuchs, T L Gavan, E H Gerlach.   

Abstract

Piperacillin (T-1220) is a new semisynthetic penicillin with an unusually broad spectrum of antimicrobial activity. In vitro comparisons of this drug with 6 other beta-lactam antimicrobics (ticarcillin, carbenicillin, ampicillin, cephalothin, cefamandole and cefoxitin) were conducted. These included minimal inhibitory concentrations (MIC) against 394 bacterial isolates, the minimal lethal concentrations (MLC) against 79 of those, as well as the effect of inoculum size on the MIC and MLC of the drugs. Piperacillin had significantly greater activity than did the other penicillins against Pseudomonas species and Klebsiella pneumoniae. Against P. aeruginosa piperacillin was 8- and 16-fold more active than ticarcillin and carbenicillin, respectively. The MLC of piperacillin rarely differed from the MIC by more than one log2 dilutions except against P. aeruginosa in which the MLC was 4-fold greater or more than the MIC of 45% of isolates tested. Ticarcillin, carbenicillin and cefoxitin showed minimal inoculum size effects. Cefamandole results showed the greatest inoculum size variation with 55% and 37% of isolates showing an 8-fold increase in MIC and MLC respectively by increasing inoculum from 10(5) to 10(7) CFU/ml. Piperacillin was intermediately effected having 25% of strains greater than 8-fold increase in MIC.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 599084     DOI: 10.7164/antibiotics.30.1107

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  12 in total

1.  Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin.

Authors:  D Phaneuf; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

2.  Analysis of the interactions between piperacillin, ticarcillin, or carbenicillin and aminoglycoside antibiotics.

Authors:  P Chanbusarakum; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Quantitative assessment of bactericidal activities of beta-lactam antibiotics by agar plate method.

Authors:  G Masuda; S Tomioka
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

4.  In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  M D Lyon; K R Smith; M S Saag; G A Cloud; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  Comparative evaluation of piperacillin in vitro.

Authors:  G M Dickinson; T J Cleary; T A Hoffman
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

6.  Comparative in vitro antibacterial activity of seven semi-synthetic penicillins against aerobic gram-negative bacteria and enterococci.

Authors:  A Thabaut; J L Durosoir; P Saliou
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 7.  Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-01       Impact factor: 9.546

8.  Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.

Authors:  G L Simon; D R Snydman; F P Tally; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

9.  Cefoperazone (T-1551), a new semisynthetic cephalosporin: comparison with cephalothin and gentamicin.

Authors:  R N Jones; P C Fuchs; A L Barry; T L Gavan; H M Sommers; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

Review 10.  Ticarcillin: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.